Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Daxor Corporation (DXR) is a medical device and diagnostics company operating within the healthcare technology and clinical diagnostics industries. The company’s core focus is the development, commercialization, and clinical support of proprietary blood volume measurement technology used to aid physicians in diagnosing and managing complex cardiovascular and critical care conditions. Daxor’s primary revenue driver is the sale and clinical utilization of its flagship diagnostic system, which is used by hospitals, academic medical centers, and specialty clinics.
The company’s primary product is the BVA‑100® Blood Volume Analyzer, a FDA‑cleared diagnostic system designed to provide precise, quantitative measurements of a patient’s blood volume and its components. This technology is positioned as a differentiator in clinical decision-making where traditional vital signs and imaging may be insufficient. Daxor was founded in the 1970s and became a publicly traded company in 1978, evolving from a research-oriented enterprise into a specialized medical technology company with a narrow but defensible clinical niche.
Business Operations
Daxor operates as a single‑segment business focused on blood volume diagnostics and related clinical services. Revenue is generated through a combination of device placements, testing services, and consumables associated with the BVA‑100® Blood Volume Analyzer. The company emphasizes recurring clinical use rather than high-volume capital equipment sales, aligning its model with diagnostic utilization within hospital systems.
Operations are primarily domestic, with clinical installations and services concentrated in the United States. The company controls its proprietary measurement technology, associated intellectual property, and clinical protocols. Public disclosures indicate no material operating subsidiaries or joint ventures; business activities are conducted directly by Daxor Corporation, and any additional partnerships are limited to hospital or academic collaborations rather than equity-based alliances. Data inconclusive based on available public sources regarding any undisclosed international licensing arrangements.
Strategic Position & Investments
Daxor’s strategic direction centers on expanding clinical adoption of quantitative blood volume analysis, particularly in heart failure, critical care, and complex fluid management cases. Growth initiatives have focused on increasing peer‑reviewed clinical evidence, engaging key opinion leaders, and integrating the BVA‑100® Blood Volume Analyzer into established treatment protocols rather than pursuing broad product diversification.
The company has historically emphasized internal development over large-scale acquisitions. Public filings do not indicate material acquisitions or a diversified investment portfolio. Strategic investments are primarily directed toward clinical research, regulatory compliance, and incremental technology enhancements. Data inconclusive based on available public sources regarding involvement in emerging digital health platforms beyond the core blood volume technology.
Geographic Footprint
Daxor is headquartered in the United States, with its principal offices and operational management located domestically. The company’s commercial and clinical footprint is concentrated in North America, where regulatory clearance, reimbursement pathways, and clinical adoption are most developed for its technology.
While the BVA‑100® Blood Volume Analyzer has been referenced in international clinical literature, Daxor’s direct operational presence outside the United States appears limited. There is no verified evidence of significant foreign subsidiaries or manufacturing facilities abroad, and international influence is primarily indirect through academic research and clinical publications rather than direct commercial operations.
Leadership & Governance
Daxor was founded by Michael Feldschuh, who continues to play a central role in shaping the company’s strategic and clinical vision. Leadership emphasizes evidence‑based medicine, conservative capital deployment, and long‑term clinical validation over rapid commercialization. Corporate governance reflects the company’s small size and focused business model.
Key executives reported in public filings include:
- Michael Feldschuh – Chief Executive Officer, President, and Chairman
- Michael Feldschuh – Founder
Data inconclusive based on available public sources regarding additional named executive officers beyond those disclosed in recent SEC filings, as the company reports a highly centralized executive structure.